- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00078195
Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered With Omalizumab, an Anti-IgE Monoclonal Antibody (ITN019AD)
Study Overview
Status
Conditions
Detailed Description
Allergic rhinitis affects 20 to 40 million Americans annually. Allergy symptoms, which can range from mild to seriously debilitating, may affect quality of life. Left untreated, allergic rhinitis can exacerbate or trigger more serious conditions, such as asthma and sinus inflammation.
Individuals with allergies react to harmless particles such as dust or pollen. Proteins in the blood called IgE antibodies treat the harmless particles as invaders and trigger an immune system response. The immune response results in harmful inflammation of healthy tissues. In ragweed allergy, inflammation occurs in the airways and causes familiar allergy symptoms like sneezing, coughing, and general discomfort.
Omalizumab is an investigational drug that has been shown to block the effects of IgE antibodies. The blocking effect of omalizumab is temporary, but giving the drug to people before their regular allergy shots may make the shots more effective.
Participants in this study will be randomly assigned to receive injections of omalizumab or a placebo before an accelerated course of allergy shots (given over 12 weeks). The participants will return for follow-up for up to one year, and they may have as many as 27 study visits.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
-
Nebraska
-
Omaha, Nebraska, United States, 68131
- Creighton University
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- University of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Able to comprehend and grant a witnessed, written informed consent prior to any study procedures.
- Female participants of child bearing age must have a negative urine pregnancy test at Screening Visit and subsequent visits. In addition, female participants must be using a medically acceptable form of birth control.
- History of seasonal allergic rhinitis for at least 2 years with symptoms during the ragweed pollen season requiring pharmacotherapy.
- A positive skin test by prick method to ragweed pollen at the Screening Visit. A positive skin prick test will be defined as a ragweed pollen-induced wheal greater than 3 mm larger in diameter than diluent control (measurements will be made 15-20 minutes after application).
- Must be capable of faithfully completing the diary and of attending regularly scheduled study visits.
- Must intend to remain in the ragweed pollen area during the entire ragweed season.
- Willing to avoid prohibited medications for the periods indicated in the protocol.
- Participants must meet pretrial eligibility requirements for trial enrollment (acceptable medical history, physical examination results, normal electrocardiogram and acceptable laboratory test results).
- Participants must have a baseline serum Immunoglobulin E (IgE) level greater than 10 and less than 700 IU/mL.
Exclusion Criteria
- weigh less than 30 kg or more than 120 kg.
- pregnant or lactating.
- history of severe anaphylactoid (non-IgE mediated) or anaphylactic reactions).
- history of immunotherapy within the past 10 years, if received one full year of immunotherapy, or within the past 5 years if received less than one year of immunotherapy.
- known hypersensitivity to trial rescue medication (fexofenadine HCl).
- taking beta-adrenergic antagonists in any form.
- taking allergic ophthalmologic medication.
- clinically significant perennial rhinitis that would interfere in assessment of ragweed-induced seasonal allergic rhinitis symptoms.
- Presence of a severely deviated nasal septum, septal perforation, structural nasal defect or large nasal polyps causing obstruction.
- History of an upper respiratory or sinus infection requiring treatment with an antibiotic within 2 weeks prior to Screening Visit.
- Documented evidence of acute or significant chronic sinusitis, as determined by the Investigator.
- Asthma (either history of, abnormal spirometry, [forced expiratory volume in 1 second (FEV1) less than 80% predicted] or use of asthma medications).
- Chronic or intermittent use of inhaled, oral, intra-muscular, or intra-venous corticosteroids; or chronic or intermittent use of topical corticosteroids within 4 weeks of Visit Screening Visit.
- Chronic use of medications (e.g., tricyclic antidepressants) that would affect assessment of the effectiveness of the study medication.
- Rhinitis medicamentosa.
- History or presence of significant renal, hepatic, neurologic, cardiovascular, hematologic, metabolic, cerebrovascular, respiratory, gastrointestinal or other significant medical condition including, autoimmune or collagen vascular disorders, aside from organ-specific autoimmune disease limited to the thyroid that in the Investigator's opinion could interfere with the study or require medical treatment that would interfere with the study.
- History of cancer other than basal cell carcinoma of the skin.
- History within the past year of excessive alcohol intake or drug addiction.
- Current smokers, greater than 10 pack year history, or participants who quit smoking less than one year prior to Screening.
- Use of any prohibited concomitant medications during the washout period (i.e., before screening) and throughout the study period.
- Participants currently undergoing immunotherapy.
- Participants with clinically significant abnormality on 12-lead Electrocardiogram (ECG) on screening visit.
- Treatment with an experimental, non-approved drug, or investigational drug within the past 30 days.
- Participants with a history of noncompliance to medical regimens and participants who are considered potentially unreliable.
- Previous treatment with a monoclonal antibody for any reason including anti-IgE in any form (e.g., omalizumab).
- Participants with known hypersensitivity to trial drug ingredients (i.e., sucrose, histidine, polysorbate 20) or related drugs (i.e., monoclonal antibody; polyclonal gamma-globulin).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Omalizumab pre-treatment, ragweed RIT, omalizumab + ragweed IT
Participants are pre-treated with omalizumab followed by ragweed rush immunotherapy (RIT) followed by dual therapy with omalizumab plus ragweed immunotherapy (IT).
|
A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered.
Omalizumab is administered in two separate phases.
In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state.
Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
Other Names:
RIT will consist of a series of injections containing ragweed extract.
The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
|
Experimental: Omalizumab pre-treatment, omalizumab
Participants are pre-treated with omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with Omalizumab plus placebo immunotherapy (IT).
|
A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered.
Omalizumab is administered in two separate phases.
In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state.
Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
Other Names:
The placebo for rush immunotherapy will contain the diluents and histamine.
The placebo for immunotherapy will contain the diluents and histamine.
|
Active Comparator: Ragweed RIT, ragweed IT
Participants are pre-treated with placebo omalizumab followed by ragweed rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus ragweed immunotherapy (IT).
|
RIT will consist of a series of injections containing ragweed extract.
The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
|
Placebo Comparator: Placebo
Participants are pre-treated with placebo omalizumab followed by placebo rush immunotherapy (RIT), followed by dual therapy with placebo omalizumab plus placebo immunotherapy (IT).
|
The placebo for rush immunotherapy will contain the diluents and histamine.
The placebo for immunotherapy will contain the diluents and histamine.
The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Average daily allergy severity score
Time Frame: 2003 ragweed pollen season
|
The average daily allergy severity score will be calculated from participants' 5 symptom scores (sneezing; rhinorrhea/runny nose; itchy nose, throat, and palate; itchy, watery eyes; and nasal congestion/stuffiness) during the ragweed pollen season.
Symptom scores are recorded twice daily (AM and PM).
The sum of the individual symptom scores will be averaged over AM and PM to give a daily score.
Each daily score will then be averaged to obtain one measure of the average daily allergy severity score for each participant.
The ragweed pollen season begins when the ragweed pollen counts rise to 10 ragweed pollen grains/m3/24 hours or above on two consecutive recorded days, and the ragweed pollen season ends when the ragweed pollen counts fall below 10 ragweed pollen grains/m3/24 hours on two consecutive recorded days.
The ragweed pollen season is from approximately August 15, 2003 to October 1, 2003, but varies among the sites.
|
2003 ragweed pollen season
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of adverse events
Time Frame: 2003 ragweed pollen season
|
The ragweed pollen season begins when the ragweed pollen counts rise to 10 ragweed pollen grains/m3/24 hours or above on two consecutive recorded days, and the ragweed pollen season ends when the ragweed pollen counts fall below 10 ragweed pollen grains/m3/24 hours on two consecutive recorded days.
The ragweed pollen season is from approximately August 15, 2003 to October 1, 2003, but varies among the sites.
|
2003 ragweed pollen season
|
Number of days with rescue medication (fexofenadine HCl 60 mg) use
Time Frame: 2003 ragweed pollen season
|
The ragweed pollen season begins when the ragweed pollen counts rise to 10 ragweed pollen grains/m3/24 hours or above on two consecutive recorded days, and the ragweed pollen season ends when the ragweed pollen counts fall below 10 ragweed pollen grains/m3/24 hours on two consecutive recorded days.
The ragweed pollen season is from approximately August 15, 2003 to October 1, 2003, but varies among the sites.
|
2003 ragweed pollen season
|
Number of rescue medication capsules used
Time Frame: 2003 ragweed pollen season
|
The ragweed pollen season begins when the ragweed pollen counts rise to 10 ragweed pollen grains/m3/24 hours or above on two consecutive recorded days, and the ragweed pollen season ends when the ragweed pollen counts fall below 10 ragweed pollen grains/m3/24 hours on two consecutive recorded days.
The ragweed pollen season is from approximately August 15, 2003 to October 1, 2003, but varies among the sites.
|
2003 ragweed pollen season
|
Rhinoconjunctivitis quality of life (QOL) questionnaire (RQLQ) scores
Time Frame: 2003 ragweed pollen season
|
The ragweed pollen season begins when the ragweed pollen counts rise to 10 ragweed pollen grains/m3/24 hours or above on two consecutive recorded days, and the ragweed pollen season ends when the ragweed pollen counts fall below 10 ragweed pollen grains/m3/24 hours on two consecutive recorded days.
The ragweed pollen season is from approximately August 15, 2003 to October 1, 2003, but varies among the sites.
|
2003 ragweed pollen season
|
Daily morning allergy symptom scores
Time Frame: 2003 ragweed pollen season
|
The ragweed pollen season begins when the ragweed pollen counts rise to 10 ragweed pollen grains/m3/24 hours or above on two consecutive recorded days, and the ragweed pollen season ends when the ragweed pollen counts fall below 10 ragweed pollen grains/m3/24 hours on two consecutive recorded days.
The ragweed pollen season is from approximately August 15, 2003 to October 1, 2003, but varies among the sites.
|
2003 ragweed pollen season
|
Daily nighttime allergy symptom scores during the 2003 ragweed season
Time Frame: 2003 ragweed pollen season
|
The ragweed pollen season begins when the ragweed pollen counts rise to 10 ragweed pollen grains/m3/24 hours or above on two consecutive recorded days, and the ragweed pollen season ends when the ragweed pollen counts fall below 10 ragweed pollen grains/m3/24 hours on two consecutive recorded days.
The ragweed pollen season is from approximately August 15, 2003 to October 1, 2003, but varies among the sites.
|
2003 ragweed pollen season
|
Individual allergy symptom scores during the 2003 ragweed season
Time Frame: 2003 ragweed pollen season
|
The ragweed pollen season begins when the ragweed pollen counts rise to 10 ragweed pollen grains/m3/24 hours or above on two consecutive recorded days, and the ragweed pollen season ends when the ragweed pollen counts fall below 10 ragweed pollen grains/m3/24 hours on two consecutive recorded days.
The ragweed pollen season is from approximately August 15, 2003 to October 1, 2003, but varies among the sites.
|
2003 ragweed pollen season
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Thomas Casale, MD, Creighton University
Publications and helpful links
General Publications
- Nayak A, Casale T, Miller SD, Condemi J, McAlary M, Fowler-Taylor A, Della Cioppa G, Gupta N. Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2003 Sep-Oct;24(5):323-9.
- Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y; Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006 Jan;117(1):134-40. doi: 10.1016/j.jaci.2005.09.036. Epub 2005 Dec 2.
- Klunker S, Saggar LR, Seyfert-Margolis V, Asare AL, Casale TB, Durham SR, Francis JN; Immune Tolerance Network Group. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol. 2007 Sep;120(3):688-95. doi: 10.1016/j.jaci.2007.05.034. Epub 2007 Jul 12.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Immune System Diseases
- Hypersensitivity, Immediate
- Otorhinolaryngologic Diseases
- Respiratory Hypersensitivity
- Nose Diseases
- Rhinitis, Allergic
- Hypersensitivity
- Rhinitis
- Rhinitis, Allergic, Seasonal
- Physiological Effects of Drugs
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Immunoglobulins
- Immunologic Factors
- Antibodies, Monoclonal
- Omalizumab
Other Study ID Numbers
- DAIT ITN019AD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Individual Participant Data Set
Information identifier: SDY1Information comments: ImmPort study identifier is SDY1
-
Study Protocol
Information identifier: SDY1Information comments: ImmPort study identifier is SDY1
-
Study design, -summary, -files, -interventions, participant schedule of events, -demographics, et al.
Information identifier: SDY1Information comments: ImmPort study identifier is SDY1
-
Individual Participant Data Set
Information identifier: CASALE ITN019ADInformation comments: TrialShare study identifier is CASALE ITN019AD
-
Study protocol synopsis; -schedule of assessments; -data and reports; -specimens availability et al.
Information identifier: CASALE ITN019ADInformation comments: TrialShare study identifier is CASALE ITN019AD
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypersensitivity
-
National Institute of Allergy and Infectious Diseases...Consortium of Food Allergy ResearchCompletedMilk Hypersensitivity | Egg Hypersensitivity | Food Hypersensitivity | Peanut HypersensitivityUnited States
-
Ospedale Buon Consiglio FatebenefratelliCompleted- Egg HypersensitivityItaly
-
IRCCS Burlo GarofoloCompleted
-
National Institute of Allergy and Infectious Diseases...Consortium of Food Allergy ResearchCompletedHypersensitivity | Food Hypersensitivity | Peanut Hypersensitivity | Immediate HypersensitivityUnited States
-
Johns Hopkins UniversityCompletedFood Hypersensitivity | Peanut Hypersensitivity | Immediate HypersensitivityUnited States
-
Allertein Therapeutics, LLCConsortium of Food Allergy ResearchCompletedHypersensitivity | Food Hypersensitivity | Peanut Hypersensitivity | Immediate HypersensitivityUnited States
-
University of North Carolina, Chapel HillWithdrawnNut Hypersensitivities
-
Alton MeltonThe Cleveland ClinicActive, not recruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)Completed
-
National Institute of Allergy and Infectious Diseases...Consortium of Food Allergy ResearchCompletedHypersensitivity | Food Hypersensitivity | Hypersensitivity, Immediate | Peanut HypersensitivityUnited States
Clinical Trials on omalizumab
-
Massachusetts General HospitalGenentech, Inc.CompletedNasal Polyps | Chronic RhinosinusitisUnited States
-
Medical University of SilesiaCentrum Medyczne Andrzej BożekNot yet recruitingAsthma, Allergic
-
Novartis PharmaceuticalsCompletedCHRONIC SPONTANEOUS URTICARIAFrance
-
NovartisGenentech, Inc.; TanoxCompletedAsthmaUnited States, Argentina, Germany
-
Boston Children's HospitalStanford UniversityCompleted
-
IRCCS Policlinico S. MatteoCompletedInterstitial Cystitis | Painful Bladder SyndromeItaly
-
Bernstein Clinical Research CenterWithdrawn
-
The University Clinic of Pulmonary and Allergic...UnknownAllergy | Immunotherapy | Omalizumab | Bee VenomSlovenia
-
Stanford UniversityCompletedAtopic DermatitisUnited States